Egypt Targets $100 Billion in Non-Oil Exports by 2030
Prime Minister announces non-oil export target amid rising inflation
Translated by Qiyas from الراي — Original source
The Egyptian Central Agency for Public Mobilization and Statistics (CAPMAS) report revealed that the annual inflation rate for the entire country stood at 12.8 percent in September 2026, compared to 12.7 percent in August 2026, representing a slight increase of 0.1 percent. Meanwhile, the general consumer price index for the entire republic reached 294.2 points in September 2026, marking an increase of 1.5 percent over August 2026.
The main reasons cited include a 0.4 percent rise in the group of cereals and bread, a 2.5 percent increase in the meat and poultry group, a 1.2 percent rise in fish and seafood, a 0.4 percent increase in dairy products, cheese, and eggs, and a 0.3 percent rise in oils and fats.
For his part, Prime Minister Dr. Mostafa Madbouly stated that the government aims to reach $100 billion in non-petroleum exports by 2030, to enhance the state’s foreign currency reserves and support the national economy.
He added, during an interview with CNN Business, that this target is part of a shift toward building a real economy based on stable productive sectors, which contributes to reducing reliance on external factors amid uncertainty regarding their developments in the coming period.
On the occasion of Egyptian President Abdel Fattah el-Sisi’s visit to Malaysia, a recent report issued by CAPMAS revealed that the value of Egyptian exports to Malaysia rose to $68 million during the first eight months of 2026, compared to $60 million during the same period in 2025, an increase of 13.3 percent. Meanwhile, the value of Egyptian imports from Malaysia reached $427 million during the first eight months of 2026, compared to $456 million during the same period in 2025, a decrease of 6.4 percent.
A report on Egypt’s external trade data revealed that Egypt imported contraceptives, cancer treatments, organ transplant medications, and cardiovascular drugs, alongside synthetic plasma substitutes and medications for intractable, chronic, psychiatric, and neurological diseases, with a total value of $717.01 million in the first half of 2026.
